Daily Stock List
Labor SMART, Inc. (LTNC)
GoldmanStockReport, AwesomePennyPicks, and ExclusiveStockAlerts reported today on Labor SMART, Inc. (LTNC), and today we highlight the Company as "One to Watch" next week here at the QualityStocks Daily Newsletter.
Labor SMART, Inc. provides on-demand temporary staffing to an assortment of industries. The Company was established to provide a reliable, dependable, and flexible resource for on-demand personnel to small and large businesses. Their goal is to become a nationwide resource and partner for their clients. Currently, Labor SMART operates six branch locations in the Southeast U.S. Founded in 2011, the Company lists on the OTC Bulletin Board and has their headquarters in Hiram, Georgia.
Their mission is to be the provider of choice to their growing community of customers, with a service-focused approach, which positions the Company as a resource and partner for their business. Labor SMART provides labor, daily, for jobs in construction, manufacturing, hospitality, events, restoration, warehousing, retail, disaster relief and more. For longer term staffing needs, Labor SMART screens every employee to make sure the right person is placed in the right job. Businesses can fill out an online form on the Company's website to get a free pricing quote.
The Company's clients range from small businesses to Fortune 100 companies. Labor SMART's current locations are in Nashville and Chattanooga, Tennessee; Augusta and Marietta, Georgia; Greenville, South Carolina; and Birmingham, Alabama. The Company is one of the fastest growing temporary labor providers. Their staffing professionals help businesses meet their immediate production deadlines, staff shortages, or short-notice temporary labor requirements.
Last month, Labor SMART announced that they generated revenues in excess of $7.1 million for 2012. In their first full year of operations, Labor SMART was successful in increasing their footprint into two additional states while expanding branch offices in early 2012. In 2011, they had set a revenue goal of $7 million for 2012, which was successfully achieved. This week, Labor SMART announced that they achieved Year-to-Date revenue of $1.15 million as of February 15, 2013.
The Company expects that additional expansion branches will follow as they continue to execute their business model in working towards a national presence. Labor Smart, under the current model, anticipates expanding into three additional states while developing 12 more branches during 2013. They said this week that they identified three additional markets for potential branch locations. Those markets are Louisville, Kentucky, Kansas City, Missouri, and Columbia, South Carolina.
Yesterday, Labor SMART announced that the Company is relocating their corporate office. Mr. Ryan Schadel, CEO, stated, "We have outgrown our current corporate facility on Darby's Crossing Drive, which is located in a business park in Hiram, GA. The new facility is nearly double the size of the current office and will give us the space needed to accommodate additional corporate staff that will be coming on board with Labor SMART. The lease was executed earlier this week and corporate staff will be relocated to the new facility at 5604 Wendy Bagwell Pkwy in Hiram over the next few days."
We're tracking Labor Smart, Inc. (LTNC) on our radar screens as "One to Watch" this week, here at the QualityStocks Daily Newsletter.
Labor Smart, Inc. (LTNC), closed Friday's trading session at $0.73, up 30.36%, on 114,118 volume with 80 trades. The average volume for the last 60 days is 30,007 and the stock's 52-week low/high is $0.10/$0.82.
Revolutionary Concepts, Inc. (REVO)
Stock Analyzer reported this week on Revolutionary Concepts, Inc. (REVO), Lions of Wall Street, Greenbackers and Pennystocktweeters.com did earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTCQB, Revolutionary Concepts, Inc. is a development stage company that focuses on the design and development of the Eye Talk Communicator - a smart camera technology. It serves as an entry management system. It gives users the ability to remotely and interactively monitor through two-way communication and control an IP camera while using a personal communication device. Revolutionary Concepts is based in Charlotte, North Carolina and the Company has consultants located across the United States
More uses for the Eye Talk Communicator include medical applications, a sporting component, and infant care technology. Eye Talk offers intuitive and independent capabilities and sits upon a platform that interfaces effortlessly with smart devices including iPhones, iPads, Blackberry's, and Androids. Revolutionary Concepts holds patented and patent pending applications that use smart camera technology in medical/healthcare, sporting events, child monitoring and many other key areas.
The Company incorporates a camera, built-in Web server, and network interface. It can manage areas of importance independently by providing programmable audio or by alerting designated users by way of an audio/video transmission to a smart phone or other compatible device. Features of Eye Talk include pre-recorded messaging capabilities; high-level security; convenient, flexible communication; instant identification; data collection and reporting; an archival system, and real time, two-way communication by way of computer, cell phone or PD.
Eye Talk technology offers administration portal management; motion activated connectivity, and remote control of PC-controller and camera. The technology also offers multi-level reporting capabilities and an expandable software platform.
At the end of January 2013, Revolutionary Concepts announced that IQmagine, LLC completed the initial product development of the toy project. Enventys, a company located in Charlotte, North Carolina dedicated to new innovative product development, sales, branding and licensing, conducted the product development. With the completion of product development for the toy-monitoring project, the next stage, licensing, is underway. IQmagine engages in the development of the next generation child transportation seat embedded with the EyeTalk Smart Camera. In addition, IQmagine is developing a toy project that will allow remote monitoring, 2-way communication and direct interface with handheld devices.
Revolutionary Concepts, Inc. (REVO), closed Friday at $0.0039, down 9.30%, on 11,536,652 volume with 71 trades. The average volume for the last 60 days is 14,719,024 and the stock's 52-week low/high is $0.0006/$0.048.
SANUWAVE Health, Inc. (SNWV)
Titan Stocks, Gladiator Stocks, Stockpicktrading, Ox of Wallstreet, Penny Stock Alley, Free Penny Alerts, Free Investment Report, Explicit Penny Picks, InsidersLab, PennyPic, KillerPennyStocks, and VictoryStocks, reported earlier on SANUWAVE Health, Inc. (NGRC), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTCBB, SANUWAVE Health, Inc. is a regenerative medicine company with corporate headquarters in Alpharetta, Georgia. They focus on the development and commercialization of noninvasive, biological response activating devices for the repair and regeneration of tissue, musculoskeletal, and vascular structures. Their portfolio of products and product candidates activate biologic signaling and angiogenic responses. This includes new vascularization and microcirculatory improvement. These responses help to restore the body's normal healing processes and regeneration.
SANUWAVE Health's plan is to apply their Pulsed Acoustic Cellular Expression (PACE) technology in wound healing, orthopedic/spine, plastic/cosmetic, and cardiac conditions. The Company's lead product candidate for the global wound care market, dermaPACE, is CE marked. It has Canadian device license approval for the treatment of the skin and subcutaneous soft tissue. In the U.S., dermaPACE is currently under the Food and Drug Administration's (FDA's) Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers.
The Company researches, designs, manufactures, markets, and services their products worldwide. They believe they have demonstrated that their technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through their U.S. Class III PMA approved Ossatron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of their Ossatron, Evotron®, and orthoPACE® devices in Europe.
Currently, SANUWAVE Health does not have any commercial products in the United States. They are presently garnering revenues from the sales of CE Marked devices and accessories in Europe, Canada and Asia. The Company is now entirely focused on developing their PACE technology.
In mid-November 2012, SANUWAVE Health reported financial results for the three and nine months ended September 30, 2012. Financial highlights for the three months ended September 30, 2012 include
Revenues increasing by 10 percent, to $178,256 compared to the three months ended September 30, 2011. Gross Profit as a percentage of revenue increased to 75 percent, up from 70 percent in 2011. Total operating expenses decreased by $695,227, or 32 percent, to $1,499,714.
SANUWAVE Health, Inc. (SNWV), closed at $0.27, even for the day, on 17,300 volume with 8 trades. The average volume for the last 60 days is 7,619 and the stock's 52-week low/high is $0.09/$0.53.
CytoCore, Inc. (CYOE)
OTCPicks, The Stock Psycho, Topgun stockpicks, Pumps and Dumps, Top Gun, and Nebula Stocks reported earlier on CytoCore, Inc. (CYOE), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
CytoCore, Inc. is developing an integrated suite of cost-effective products for the detection, diagnosis and treatment of cancer under the trade name of CytoCore Solutions. The intention of the Company's products is to address sample collection, specimen preparation, specimen evaluation (including detection/screening and diagnosis), and patient treatment and monitoring within vertical markets related to specific cancers. At present, CytoCore has one of their own products for sale - SoftPAP collectors.
CytoCore's shares trade on the OTC Bulletin Board. The Company has their headquarters in Chicago, Illinois. The Company formerly went by the name Molecular Diagnostics, Inc. They changed their name to CytoCore, Inc. in June of 2006. Their business strategy is to develop products by way of internal development processes, strategic partnerships, licenses, as well as acquisitions.
Current CytoCore Solutions products are focusing on cervical cancer. The Company's plan is to expand their focus to include other gynecological cancers as well as bladder, lung and breast cancers, among others. Within each of these markets, CytoCore's anticipation is that the CytoCore Solutions products will sell as individual value-added drop-in replacements for existing products and as integrated systems that improve the efficiency and effectiveness of clinical and laboratory operations.
The Company has developed the SoftPAP; a sample collection device approved by the U.S. Food and Drug Administration. SoftPAP is a device for the collection of cervical cell samples that are used in the detection of cervical dysplasia, cancer, and human papillomavirus infections.
CytoCore has licensing to sell the PadKit collection device and GluCyte cell preservative. PadKit is a sample collection device that ensures female reproductive tract health. CytoCore is focusing on the development and testing of cocktail assay markers and stains for use with their Automated Image Proteomic System (AIPS) to screen for various cancers. In addition, the Company markets and sells a companion product, manufactured by a third party, designed to detect breast cancer.
CytoCore, Inc. (CYOE), closed Friday's trading session at $0.0189, up 89.00%, on 15,150 volume with 4 trades. The average volume for the last 60 days is 22,037 and the stock's 52-week low/high is $0.005/$0.08.
Earn-A-Car, Inc. (EACR)
Today we are highlighting Earn-A-Car, Inc. (EACR), here at the QualityStocks Daily Newsletter.
Incorporated in 2005, Earn-A-Car, Inc., via their subsidiary, provides mid to low-range automobiles to people with sub-prime credit on a "rent-to-own" basis. The structuring of the Company's business model is to leverage the opportunity that exists in the southern African market, where cars for personal and business use are in high demand, but where traditional bank financing is very difficult to access. The Company's plan of operation for this year is to continue to expand their business to meet demand for their services. Earn-A-Car's shares trade on the OTC Markets' OTCQB. The Company is based in Benoni, South Africa.
Earn-A-Car offers rental of vehicles to retail customers through company-owned stores. All vehicles are fitted with the latest in anti-theft technology. They are also fitted with "disabling" devices. This allows for the Company's vehicles to be immobilized and retrieved immediately in the event of theft, or non-payment by the customer (monthly in advance). Consequently, Earn-A-Car's bad debts are minimal. Loyal customers are rewarded for each completed month with cash back. Generally, over 4 years, this is enough to buy the car from Earn-A-Car.
On January 11, 2013, Earn-A-Car reported that the Company purchased an additional 81 vehicles in the last quarter. Their fleet size at the end of the quarter was 636 vehicles (2012/08: 577). Of these, 553 were rented out (2012/08: 460). These additional vehicles have substantially increased the Company's annuity and revenues.
The Company's Management believes the increase in fleet size will increase income over the next few quarters. Earn-A-Car expects to continue to increase the fleet regularly through 2013. The Company will seek additional funding in the last quarter of 2013, to enable them to continue to grow in the next year.
For the quarter ended November 30, 2012 versus the quarter ended November 30, 2011, Earn-A-Car's Revenues increased from $642,562 in Q3 of FY 2012 to $1,051,416 in Q3 of FY 2013. This represents an increase of $408,854 or 64 percent. The Company's operating expenses went from $525,279 in Q3 of FY 2012 to $790,258 in Q3 of FY 2013. This represents an increase of $264,979 or 50 percent. Expenses rose primarily because of the Direct Costs related to the purchasing of vehicles and the additional depreciation on vehicles due to the increased fleet size. Net income increased from $117,330 in Q3 of FY 2012 to $257,482 in Q3 of FY 2013.
Earn-A-Car, Inc. (EACR), closed Friday's trading session at $0.07, up 180.00%, on 61,500 volume with 7 trades. The average volume for the last 60 days is 74,270 and the stock's 52-week low/high is $0.017/$0.19.
Z-Gold Exploration, Inc. (ZGG.V)
We are reporting on Z-Gold Exploration, Inc. (ZGG.V) today, here at the QualityStocks Daily Newsletter.
Z-Gold Exploration, Inc. is an exploration company exploring for gold and base metals in the Abitibi Greenstone Belt (AGB) of Ontario and Quebec (Timmins, Matheson, Kirkland Lake, Rouyn-Noranda, Cadillac, Malartic and Val-d'Or). Z-Gold acquired the Abitibi Gold Property (Munro Township) because of the renewed interest for gold mining properties located in the famous Timmins Camp including the Matheson camp. Incorporated in 2006, the Company has their headquarters in Rouyn-Noranda, Quebec. Z-Gold Exploration's shares trade on the TSX Venture Exchange.
The Abitibi Gold property is on Pipestone and Destor Porcupine's splay faults. Z-Gold has acquired gold and base metals properties in the Casa Berardi camp (Casa Berardi Property), Matagami camp (Coda Property) and Val-d'Or mining camp (Vauquelin Property).
Concerning the Abitibi Gold Project (2,087.9 hectares), Airborne survey covering the Abitibi Gold Property and the Croesus Mine area delineated the presence of major structure and gold traps (cross faults) (drill targets). The presence of arsenic is always the indication of high-grade gold values and an exploration tool. The Company has five 21 year Leases containing 85 Mining Claims Units (91 units) and 30 claims consisting of 38 units. There exist 10 known gold zones; grab samples returned gold values as high as 2,500 g/t. The Property has never undergone drilling at depth. The Gold Zone is already stripped (600 feet long, 5 feet grading 0.20 oz/tonne).
The Casa Berardi Project comprises 96 claims located in the Casa Berardi Township. It is near the Casa Berardi Mine controlled by Aurizon Mines. There exist huge alteration zones on the property and many splay faults of the Casa Berardi Fault are present on the property.
Z-Gold's Vauquelin Project consists of six claims situated in the Vauquelin Township, Val-d'Or mining camp, Quebec. There is a strong megatem anomaly located in a favorable environment. Embayment is in the Vauquelin-Pershing batholith.
In November 2012, Z-Gold Exploration announced that their Board of Directors approved the extension of the expiry date of the 527,778 common share purchase warrants issued on December 3, 2010 for three additional years. The warrants will now expire on December 3, 2015. The exercise price of $0.26 remains the same. This modification is subject to approval of the TSX Venture Exchange.
Z-Gold Exploration, Inc. (ZGG.V), closed Friday's session at $0.05, up 66.67%, on 150,000 volume. The stock's 52-week low/high is $0.09/$0.53.
Paw4mance Pet Products International, Inc. (PAWP)
Actual Gains, AlphaPennyStock, StockRunway, and PennyStockRumors reported earlier on Paw4mance Pet Products International, Inc. (PAWP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Paw4mance® Pet Products International, Inc., via their subsidiary, distributes treats, toys, accessories as well as hygiene products. The Company has several brands, products and services currently in development. Paw4mance Pet Products is working to position their Company as an international leader in the Pet food and pet services industry.
Paw4mance established in 1993 to develop and distribute a naturally preserved (chemical free) and holistic high-end kibble. The Company produces their products in the Province of Ontario, Canada. Paw4mance Pet Products has their corporate headquarters in Toronto, Ontario. Originally based in Ontario, 2011 marked the Company's expansion into the United States and other key markets. Currently, the Paw4mance umbrella contains and operates Paw4mance holistic pet food (available in Canada) and the soon to be released MOJO® brand of holistic pet products.
Paw4mance is one of the only Pet Product companies that deliver fresh Dog food, Cat food and All Natural treats direct to customers' doors. The Company has worked to create foods and treats with no chemical preservatives, no artificial flavors, no artificial colorings, and no purposely-added fillers as well as no soy products.
The Company makes their foods with easily digestible proteins and chelated minerals and vitamins for simple absorption. They are efficiently metabolized for every stage of a pet's life.
Currently, Paw4mance Pet Products conducts operations out of two strategically located facilities. These two facilities are capable of shipping the Company's products to practically any location across
North America. Their 3000 Sq. Ft. Canadian office and distribution center is in Toronto Ontario. Their 8000 Sq. Ft. American office and distribution center is in Las Vegas, Nevada.
Today, Paw4mance Pet Products announced, that after a lengthy process, the Company has achieved DTC-ELIGIBILITY. The Company has successfully updated their filings with the OTC-Market Group to be listed under "OTC Pink Current Information". In addition, Paw4mance Pet Products has overseen the transfer to Island Stock Transfer, Clearwater, Florida as their Transfer Agent. Moreover, the Company has achieved DTC-ELIGIBILITY via the coordinated efforts of the Company's legal counsel and in cooperation with legal counsel of Island Stock Transfer.
Paw4mance Pet Products International, Inc. (PAWP), closed today at $0.11, up 633.33%, on 57,970 volume with 9 trades. The average volume for the last 60 days is 3,542 and the stock's 52-week low/high is $0.02/$0.46.
Quest Rare Minerals Ltd. (QRM)
Pro-Edge, FeedBlitz, and Streetwise Reports reported this month on Quest Rare Minerals Ltd. (QRM), Wealth Daily, Energy and Capital, The Street, Stockhouse, and TheStockAdvisor reported earlier, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Quest Rare Minerals Ltd. is an exploration enterprise focusing on the identification and discovery of new and significant Rare Earth deposit opportunities. Currently, the Company is advancing several high-potential projects in Canada's premier exploration areas: the Strange Lake and the Misery Lake areas of northeastern Quebec. Quest Rare Minerals has their corporate headquarters in Montreal Quebec; they also have an office in Toronto, Ontario.
The Company's 2009 exploration led to the discovery of a significant new Rare Earth metal deposit, the B-Zone, on their Strange Lake property. Quest has filed a National Instrument 43-101 Indicated and Inferred Resource Estimate on the B-Zone deposit. They've completed a Preliminary Economic Assessment (PEA) for the deposit. The Strange Lake Project is 225 km northeast of Schefferville, Quebec and 125 km west of the Voisey's Bay nickel-copper-cobalt deposit, eastern Labrador.
Quest also announced the discovery of an important new area of REE mineralization on their Misery Lake project, approximately 120 km south of the Strange Lake project. The Company continues to pursue high-value project opportunities throughout North America.
Last week, Quest Rare Minerals provided an update on the preparation of a Pre-Feasibility Study (PFS) for the B-Zone deposit at their Heavy Rare Earth Element Project (Strange Lake). Major development work has completed; it demonstrates that Strange Lake is a very large rare earth project with one of the highest concentrations of heavy rare earth elements and important by-products zirconium and niobium. The bulk of the engineering work for the PFS has been completed. Quest is examining potential refinements to the Strange Lake Project. Their goal is to reduce project risk further, lowering capital and operating costs, and allowing for an earlier mine commissioning date in comparison to the current project configuration.
Quest Rare Minerals recently announced that Mr. Anil Singh joined the Company's marketing and investor affairs team as Vice-President, Investor & Corporate Affairs effective February 18, 2013. Mr. Singh will lead Quest's investor affairs and marketing team and will report directly to Mr. Peter Cashin. Mr. Singh brings more than seven years of experience in the financial services and merchant banking sectors to Quest Rare Minerals. He was recently Vice President, Investment Banking with Foundation Markets, Inc.
Quest Rare Minerals Ltd. (QRM), closed Friday's trading session at $0.7151, down 3.10%, on 106,412 volume with 236 trades. The average volume for the last 60 days is 129,717 and the stock's 52-week low/high is $0.67/$3.08.
HII Technologies, Inc. (HIIT)
The QualityStocks Daily Newsletter would like to spotlight HII Technologies, Inc. (HIIT). Today, HII Technologies, Inc. closed trading at $0.14, even for the day. The stock’s average daily volume over the past 60 days is 85,210, and its 52-week low/high is $0.015/$0.22.
HII Technologies, Inc. (HIIT) is an oilfield services company serving the power, water, and safety markets with innovated solutions that are in high demand and used by exploration and production (E&P) companies. With over a decade of experience in the energy business, the company has established a solid track record as well as developed an extensive network of relationships with oil and gas E&P companies, energy consultants and advisors, vendors, suppliers, and strategic corporate partners.
HII Technologies' power subsidiary, South Texas Power, provides portably onsite diesel and natural gas generators to E&P companies that are in remote areas and don't have ready access to a power grid. AES Water Solutions, the company's water transfer division, provides above ground temporary infrastructure to transfer millions of gallons of water needed in connection with hydro-fracing of oil and gas wells. HII Technologies' safety consulting business, AES Safety Services, helps E&P companies meet the increasing state and federal requirements for 24/7 safety personnel on site from the early stages of preparing for drilling to the final completion work.
Management's relationships in the markets it operates is a key to the company's success. Matt Flemming, CEO of HII Technologies has twenty years' experience as CFO and CEO of high growth companies and ten years in oil and gas services and manufacturing markets. Brent Mulliniks, P.E., is a frac engineer by training and as President of AES Water Solutions brings significant experience and knowledge to the hydro-fracing water transfer business. Jason Cuevas, GM of South Texas Power, was previously GM of National Oilwell Varco Portable Power division in the heart of the Eagle Ford Shale in S. Texas.
The company seeks differentiation of its operating divisions by accessing and acquiring technologies, as well as evaluating joint ventures, while successfully executing its organic growth strategy. Significant growth and profitability is projected by management as the company continues to meet the needs of the ever expanding energy marketplace. Leveraging an array of competitive strengths and deep expertise in the energy services business, HII Technologies is well positioned as one of the most dynamic oilfield service companies in the United States. Disclaimer
HII Technologies, Inc. Company Blog
HII Technologies, Inc. News:
HII Technologies, Inc. Announces New Safety Services business unit
HII Technologies, Inc. Announces Preliminary 4th Quarter 2012 Results
HII Technologies, Inc. Announces Strategic Hire for its South Texas Power Division
Duma Energy Corp. (DUMA)
The QualityStocks Daily Newsletter would like to spotlight Duma Energy Corp. (DUMA). Today, Duma Energy Corp. closed trading at $2.13, up 1.43%, on 6,105 volume with 9 trades. The stock’s average daily volume over the past 60 days is 5,969, and its 52-week low/high is $1.10/$4.00.
Duma Energy Corp. (DUMA) is an aggressive growth company actively producing oil and gas in the domestic United States, both on and offshore. Leveraging its technical expertise, promising portfolio, and strong financial condition, the company plans to utilize domestic revenues and cash flow to fund its rapid growth through acquisition, while participating in transformational projects with the potential of providing exponential returns for shareholders.
The company's primary goal for fiscal year 2013 and beyond is to drive earnings growth. The company also aims to pursue listing on major exchange(s) to provide better visibility and liquidity to shareholders and financial partners. Already producing and generating revenue from oil and gas in Texas, Illinois, and Louisiana, Duma projects domestic production to exceed 2,500 boepd projected by the end of 2013.
Duma was founded in 2005 and began trading on the OTCBB in 2009 via registration. In 2006, the company began producing from its first properties in Texas and soon after added production in Louisiana. In 2009, its new CEO Jeremy G. Driver came on board. Within one year, Mr. Driver had identified and negotiated an acquisition that would fundamentally reshape the company. This acquisition was made possible by the large direct cash investment by Mr. Driver and his family, as well as other investors.
The company uses only industry standard and time-tested technologies, and avoids unproven "resource plays" and other opportunities that are heavily dependent upon high commodity prices. Not bound by any geographical location or operational strategy, Duma's management team is focused on developing its existing portfolio while pursuing additional opportunities that provide rapid growth, leveraging growing revenue, cash flow, and reserves to accelerate its growth strategy. Disclaimer
Duma Energy Corp. Company Blog
Duma Energy Corp. News:
Duma Energy Receives 1.1 Billion Barrel P10 Estimate for Namibia Concession
Hydrocarb Energy Updates Source Rock Evaluation for its Africa Concession
Duma Energy Announces Strong Year End Results
Advaxis, Inc. (ADXS)
The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.13, up 8.33%, on 8,117,469 volume with 456 trades. The stock’s average daily volume over the past 60 days is 4,719,045, and its 52-week low/high is $0.0275/$0.155.
Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer
Advaxis, Inc. Company Blog
Advaxis, Inc. News:
Advaxis Announces Phase 1/2 Trial of ADXS-HPV in Anal Cancer Conducted by Brown University Oncology Group
Chairman and CEO of Advaxis Featured in Exclusive SmallCapVoice Interview
Advaxis to Present at the 15th Annual BIO CEO & Investor Conference
Consorteum Holdings, Inc. (CSRH)
The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.0243, up 10.45%, on 37,500 volume with 3 trades. The stock’s average daily volume over the past 60 days is 168,593, and its 52-week low/high is $0.001/$0.032.
Consorteum Holdings, Inc. (CSRH) utilizes the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create customized programs for maximum results. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.
Through its exclusive software license with Tarsin Inc., the company leverages a team of software developers that understands the complexities of delivering digital media content across mobile handsets. Tarsin is capable of providing clients with integration and support for over 700 mobile carriers globally on a seamless and secure platform to take advantage of the increasing demand for rich mobile content.
Consorteum's flagship CAPSA technology platform brings a universal solution to the problems of wagering and betting on mobile devices. Multiple different operating systems, user interfaces, and form factors have created enormous barriers to launching commercial initiatives. But with CAPSA, gaming operators can now cost-effectively monetize innovative mobile wagering products and services quickly and robustly.
In addition to its mobile initiatives, Consorteum is also actively engaged in the financial industry, providing MasterCard solutions as well as loyalty and reward programs. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer
Consorteum Holdings, Inc. Company Blog
Consorteum Holdings, Inc. News:
Consorteum Holdings Inc. Reaches Funding Agreement With Private Equity Group
Consorteum Holdings Files Form 10-K Report With the Securities and Exchange Commission
CORRECTION -- Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming
If there is one thing that seems to define modern health care, it’s costs. Today, there are options that never had to be considered in the past, but options that come at a price. High-tech healthcare costs money, but most people are also glad to have such options available and wouldn’t want to go back to the old days. However, there is one area of cost that is especially controversial. The fast rising cost of pharmaceuticals is difficult for most people to appreciate. After all, one pill looks pretty much like another. But the pharmaceutical industry is quick to point out a range of factors that have fed the frightening increase in the price paid for these pills.
First and foremost is the exploding cost of research and development. One study suggests that the average cost of bringing a new drug to market has risen from $199 million in the 1970s, itself an impressive figure, to almost $1.9 billion. Further studies suggest that this 10-fold jump is due to several factors, including more time spent in clinical testing plus stricter regulations that can end up ruining years of research. The fact is drug development is far riskier today, with the chances of success much smaller than they used to be. It takes twice as long to get an approval, and the odds of getting approved at all are only about one in ten.
VistaGen Therapeutics offers a major source of help in potentially reducing these costs. The company has used its advanced proprietary stem cell technology to create a unique testing platform for new drug development called Human Clinical Trials in a Test Tube. It will allow drug development companies to greatly reduce the risks involved in drug development by giving them a way to test drugs on real human tissues while still in the lab, long before any clinical trials. Companies can thereby avoid the chance of spending huge amounts of money developing a drug only to have it get pulled in clinical trials due to heart or liver toxicity.
For additional information, visit www.VistaGen.com
The Lifeline Cell Technology subsidiary of International Stem Cell Corp. specializes in the development and manufacture of purified primary human cells and optimized reagents for cell culture. The company’s scientists are busy developing new and improved human cell systems used in testing and research by the worldwide culture marketplace and are making breakthroughs in the development of human stem cell production. The founders of Lifeline Cell Technology helped introduce Normal Human Cell Systems for research over 25 years ago, and the company continues to be an industry leader known for unequaled value, supported by meticulous quality testing, ongoing innovation, and a passion to provide the best customer and technical care.
Lifeline Cell Technology has two primary facilities in the United States:
• Frederick, Maryland, is the site of the company’s headquarters, where they have an advanced product development and production laboratory, together with administration and sales offices. These facilities have all the capabilities needed to develop, produce, support, and market human cell culture products including cells, optimized serum-free and low serum media, and reagents. Lifeline has recently expanded this facility to accommodate additional manufacturing needs, including custom media manufacturing.
• Oceanside, California, is the site of an International Stem Cell (ISCO) facility where Lifeline conducts human cell in vitro research, development, and manufacturing. ISCO, Lifeline’s parent company, is continuing to expand their cell culture facilities to include therapeutic cell research, development, and production cGMP suites.
Outside the U.S. Lifeline’s success rests in the strong relationships the company has forged with their various international distributors, including the following:
• Kurabo Bio-Medical, Osaka, Japan
• CellSystems, Troisdorf, Germany
• KDR Biotech, Seoul, Korea
• BST Scientific, Singapore
• Beijing Qingyuahao Biologics, Beijing, China
• Sristibio, Hyderabad, India
• Smartec Scientific Corp. Taipei city, Taiwan
For additional information, visit www.InternationalStemCell.com and www.LifelineCellTech.com.
Rainbow Coral, through their wholly-owned subsidiary Rainbow Biosciences, seeks partnership with biotechnology developers to deliver profitable new medical technologies and innovations, focusing on commercialization potential in key areas such as Alzheimer’s, Parkinson’s, and cancer.
An example of the company’s activities is their joint venture partnership with Nano3D BioSciences (n3D), a Texas company with a unique technology for the rapid culturing of cells in three dimensions using magnetic levitation. Compared with conventional cell cultures grown on flat surfaces, these 3D cultures form tissues that more closely resemble those found in the human body. The technique has the potential to drastically reduce the cost of developing new drugs as well as eliminate the use of animals when testing the safety of manufactured chemicals. Remarkably, the magnetic levitation technology that Nano3D BioSciences currently offers to grow such things as lifelike human lung tissue could one day lead to lab-grown, implantable human organs.
RBCC CEO, Patrick Brown, commented on the Bio-Assembler technology and on Dr. Souza, one of its co-inventors/creators: “Nano3D’s Bio-Assembler technology was recently used to create the first lab-grown lung tissue with organized layers of cells, and incredibly enough, that’s only the tip of the iceberg. Dr. Souza and n3D are truly on the cutting edge of regenerative medicine, and we couldn’t be more excited to help market it to elite laboratories and researchers around the globe.”
Last year, Rainbow BioSciences, RBCC’s biotech division, signed a joint venture agreement with n3D to help develop and market the Bio-Assembler. The system utilizes a proprietary process that enables scientists to grow cells in a three-dimensional environment using nanoparticles that produce magnetic fields to lift cells from the bottom of petri dishes. Rainbow BioSciences plans to develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb, Abbott Laboratories, and Amgen.
For additional information, visit the company’s website at www.RainbowbioSciences.com
Alvarion, a provider of highly optimized wireless broadband capabilities with a portfolio of solutions spanning across licensed and unlicensed spectrums, was reported today by leading private global telecom solutions provider, Telrad Networks, as having agreed to Telrad’s $6.1M acquisition offer on ALVR’s broadband wireless access (BWA) division.
In addition to the reported sticker price, the deal also stipulates that Alvarion may receive performance-based milestone payments up to $6M, which isn’t much of a leap of faith, considering the burgeoning growth of BWA technology across the massive global wireless broadband space. The incredibly transformative effect of disseminating internet access via such technology to locations all over the planet that have little to no infrastructure is profound indeed and thus the giant movements within the sector in recent years.
Alvarion’s BreezeCOMPACT is a perfect representation of this new tech paradigm’s potential, offering providers a self-contained and extremely robust outdoor unit with a small footprint that is easily deployed and yet packs everything needed to execute a super-fast wireless broadband node all in one box. Better yet, the design is future-proofed with LTE-Advanced onboard and utilizes software-defined radio design, making this the perfect device for hitting a whole slew of supported frequencies (16e, 16e+, and LTE-A). Macro base station class performance from a tight little single-box architecture allows for modular deployment and scalable coverage footprints, something which has led to ALVR’s globe-spanning BWA division growing to over 250 current broadband carriers, as well as wireless internet service providers. Furthermore, BreezeCOMPACT makes great use of ALVR’s extremely mature and field-proven, all-IP 4Motion™ technology, which provides operators with a level of situational awareness via high interoperability and immersion in a complete ecosystem at the network level, that allows for an optimal responsiveness to emerging device and service trends.
CEO of Telrad, Ran Bukshpan, underscored the broad synergies inherent in the deal, as each company is heavily enmeshed in essentially parallel technical areas. They also have much in common when it comes to end-market engagement dynamics. It’s a natural fit really and because both firms already have an established global presence in the overall market, doing business with the same types of customers around the world, the resulting entity will be poised to capture massive territory as the rush into next-gen wireless heats up.
Bukshpan projected strong returns from BWA as an aggressive roadmap for development has already been laid out for migrating customers smoothly into the new, more powerful TD-LTE (Time-Division Long-Term Evolution) Advanced environment. Bukshpan welcomed the new personnel who will be coming over from ALVR heartily and pledged to continue serving the “impressive customer base” already established by Alvarion with the same level of consistent, dedicated customer service for which Telrad is so well-liked by their enterprise telecom clientele.
The deal is huge for ALVR and also puts the already well-positioned Telrad in the pole position to dominate substantial territory in broadband wireless access innovation. The marriage of these two entities will no doubt continue to produce newsworthy events for investors to keep track of as the stampede into the LTE-Advanced 4G standard goes hypernova, especially in emerging markets where mobile adoption by consumers is strikingly above average.
Telrad’s might as an established equipment vendor and services company, providing over 100 top global telecom operators and enterprises with all the implementation, management, and provisioning help they need to get the job done, will serve as a major springboard for ALVR’s ground-breaking product portfolio.
For more information on Alvarion, please visit www.Alvarion.com
Today's Top 3
Fast Moving Stocks
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Advaxis, Inc. (ADXS) Chairman and CEO Featured in Exclusive SmallCapVoice Interview
- Bergamo Acquisition Corp. (BGMO) Provides Authenticated Documentation to Confirm Bank Deposits
- Consorteum Holdings, Inc. (CSRH) Reaches Funding Agreement With Private Equity Group
- Cardium Therapeutics, Inc. (CXM) Announces Presentation at The 2013 Cell & Gene Therapy Forum
- Duma Energy Corp. (DUMA) Receives 1.1 Billion Barrel P10 Estimate for Namibia Concession
- GlobalWise Investments, Inc. (GWIV) CEO to Speak at Technology United Executive Conference
- HII Technologies, Inc. (HIIT) Announces New Safety Services business unit
- International Stem Cell Corp. (ISCO) Strengthens Intellectual Property Portfolio
- Loans4Less.com, Inc. (LFLS) Engages CPA Firm to Audit Financials
- Rafarma Pharmaceuticals, Inc. (RAFA) Receives General License for Pharmaceutical Products Starts Mfg. 3 New Products
- Rainbow Coral Corp. (RBCC) Retains New IR Group to Optimize Investor Outreach, Relay Key Growth Plans
- TNI BioTech Inc. (TNIB) Secures Exclusive License to Portfolio of Cancer Treatment and Prevention-Related IP
- Viaspace, Inc. (VSPC) 25 Acres of Giant King Grass Shipped and Growing in St. Croix
- Viscount Systems, Inc. (VSYS) Awarded Contract to Secure Additional U.S. Government Facilities
- VistaGen Therapeutics, Inc. (VSTA) Becomes Member of Centre for Commercialization of Regenerative Medicine Consortium